Health Care • Medical/Dental Instruments
$5.59 ▼ -0.19
(-3.29%)
MKT CAP: $113.5M • VOL: 93.9K
52W L $4 52W H $6
ROARABLE / RQD
E • 33/100
PIOTROSKI
2 / 9
PYPD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$33.0M | -$28.0M | -$22.9M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$34.2M | -$29.0M | -$23.9M |
| EBITDA (Normalized) | -$32.8M | -$28.0M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$27.9M | -$22.0M | -$17.2M |
| Capital Expenditures (CapEx) | $210.0K | $76.0K | — |
| Free Cash Flow (FCF) | -$28.1M | -$22.0M | -$17.2M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $6.4M | $15.6M | — |
| Total Debt (Short + Long Term) | — | $634.0K | — |
| Total Stockholders' Equity | $11.0M | $7.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PYPD.